Dexamethasone

• Description:

  Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist, apoptosis inducer, and common disease inducer in experimental animals, constructing models of muscle atrophy, hypertension, and depression. Dexamethasone can inhibit the production of inflammatory miRNA-155 exosomes in macrophages and significantly reduce the expression of inflammatory factors in neutrophils and monocytes. Dexamethasone also has potential for use in COVID-19 research[1][2][3][4].

• Product Name Alternative:

  Hexadecadrol; Prednisolone F

• UNSPSC:

  12352211

• Hazard Statement:

  H334, H360, H373, H410

• Target:

  ADC Payload; Antibiotic; Autophagy; Bacterial; Complement System; Glucocorticoid Receptor; Mitophagy; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related; Anti-infection; Autophagy; Immunology/Inflammation; Vitamin D Related/Nuclear Receptor

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Endocrinology; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Dexamethasone.html

• Concentration:

  10mM

• Purity:

  99.86

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |Ethanol : 8.33 mg/mL (ultrasonic)

• Smiles:

  O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2(F)[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H](C)[C@@]4(C(CO)=O)O)=C1

• Molecular Formula:

  C22H29FO5

• Molecular Weight:

  392.46

• Precautions:

  H334, H360, H373, H410

• References & Citations:

  [1]LaLone CA, et al. Effects of a glucocorticoid receptor agonist, Dexamethasone, on fathead minnow reproduction, growth, and development. Environ Toxicol Chem. 2012 Mar;31 (3) :611-22.|[2]Adcock IM, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999 Jun;127 (4) :1003-11|[3]Ballabh P, et al. Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids. Arch Dis Child Fetal Neonatal Ed. 2004 Jan;89 (1) :F76-83.|[4]Yun Chen, et al. Glucocorticoids inhibit production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses. Int J Clin Exp Pathol 2018;11 (7) :3391-3397.|[5]Yoshioka Y, et al. Glabridin inhibits dexamethasone-induced muscle atrophy. Arch Biochem Biophys. 2019 Mar 30;664:157-166.|[6]Troncoso R, et al. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle. 2014;13 (14) :2281-95.|[7]Ong SL, et al. Hemodynamics of dexamethasone-induced hypertension in the rat. Hypertens Res. 2009 Oct;32 (10) :889-94.|[8]Nakamoto H, et al. Characterization of alterations of hemodynamics and neuroendocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens A. 1991;13 (4) :587-606.|[9]Mesripour A, et al. The effect of vitamin B6 on dexamethasone-induced depression in mice model of despair. Nutr Neurosci. 2019 Oct;22 (10) :744-749. |[10]Bhatt S, et al. Role of Aspirin and Dexamethasone against Experimentally Induced Depression in Rats. Basic Clin Pharmacol Toxicol. 2016 Jul;119 (1) :10-8.|[11]Song D, et al. Physiologically Based Pharmacokinetics of Dexamethasone in Rats. Drug Metab Dispos. 2020 Sep;48 (9) :811-818.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  ACS Biomater Sci Eng. 2022 Nov 14;8 (11) :4850-4862.|ACS Chem Neurosci. 2023 Jun 21;14 (12) :2362-2374.|ACS Infect Dis. 2025 Oct 10;11 (10) :2814-2820.|ACS Nano. 2023 Dec 26;17 (24) :25377-25390.|ACS Nano. 2024 Aug 13;18 (32) :21009-21023.|ACS Nano. 2025 Mar 4;19 (8) :7728-7741.|Acta Biochim Biophys Sin (Shanghai) . 2019 Sep 6;51 (9) :908-914.|Acta Biomater. 2022 Dec:154:194-211.|Acta Pharm Sin B. 2024 Apr 23.|Acta Pharm Sin B. 2025 Aug 5.|Acta Pharm Sin B. 2025 Nov 13.|Acta Pharmacol Sin. 2020 Jan;41 (1) :10-21.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Acta Pharmacol Sin. 2022 Sep;43 (9) :2429-2438.|Acta Pharmacol Sin. 2025 Aug;46 (8) :2296-2309.|Adipocyte. 2022 Dec;11 (1) :202-212.|Adipocyte. 2022 Dec;11 (1) :562-571.|Adv Funct Mater. 2025 Apr 21.|Adv Funct Mater. 2025 May 22.|Adv Healthc Mater. 2025 Aug 11:e00602.|Adv Healthc Mater. 2025 Jun 25:e2500867.|Adv Mater. 2024 Dec 26:e2415543.|Adv Sci (Weinh) . 2022 Jan;9 (3) :e2102435.|Adv Sci (Weinh) . 2022 Sep;9 (26) :e2202505.|Adv Sci (Weinh) . 2024 Nov 2:e2406766.|Adv Sci (Weinh) . 2025 Apr 15:e2415846.|Adv Sci (Weinh) . 2025 May 30:e14902.|Adv Sci (Weinh) . 2025 Nov 14:e14514.|Adv Sci (Weinh) . 2025 Nov 21:e08472.|Adv Sci (Weinh) . 2025 Oct 28:e16569.|Allergy. 2025 Jul 25.|Am J Physiol Endocrinol Metab. 2024 May 1;326 (5) :E696-E708.|Antioxidants (Basel) . 2021 Aug 24;10 (9) :1333.|Arch Med Res. 2018 Jul;49 (5) :335-341.|Atherosclerosis. 2026 Jan:412:120594.|Authorea. 2023 Jan 27.|BIO Web of Conferences. 2025 May 12.|Bioact Mater. 2024 May 6:37:549-562.|Biochem Biophys Res Commun. 2019 Jun 11;513 (4) :1019-1026.|Biochem Biophys Res Commun. 2023 May 21:657:108-118.|Biochem Biophys Res Commun. 2024 Nov 26:735:150865.|Biochem Pharmacol. 2020 Oct;180:114145.|Biochem Pharmacol. 2025 Jun:236:116870.|Biochim Biophys Acta Mol Basis Dis. 2025 May 13:167904.|Biochim Biophys Acta Mol Cell Res. 2025 Jan 27:119911.|Biomaterials. 2020 Feb;232:119730.|Biomaterials. 2025 Jun 17:324:123513.|Biomed Pharmacother. 2021 Jul:139:111590.|Biomed Pharmacother. 2024 Apr:173:116346.|Biomed Res Int. 2022 Jul 23:2022:8080679.|Biomedicines. 2025 Mar 3;13 (3) :614.|Biomolecules. 2025 Nov 19;15 (11) :1623.|Bioorg Chem. 2022 Dec:129:106206.|bioRxiv. 2023.|bioRxiv. 2024 August 11.|bioRxiv. 2024 Jul 7:2024.07.04.601620.|bioRxiv. 2025 February 22.|bioRxiv. 2025 January 19.|bioRxiv. 2025 March 25.|Biotechnol J. 2025 Jul;20 (7) :e70080.|BMC Med. 2025 May 30;23 (1) :316.|Bone Res. 2025 Jan 26;13 (1) :18.|Bone Res. 2025 Mar 3;13 (1) :30.|Bone. 2024 Aug 3:117222.|Br J Pharmacol. 2021 Aug;178 (15) :2976-2997.|Brain Behav Immun. 2025 Sep 21:130:106118.|Cancer Res. 2025 Sep 10.|Carbohydr Polym. 2023 Jan 1:299:120179.|Cell Biochem Biophys. 2025 Jun;83 (2) :2115-2126.|Cell Biol Toxicol. 2025 Mar 7;41 (1) :56.|Cell Commun Signal. 2025 Feb 5;23 (1) :65.|Cell Mol Life Sci. 2025 Nov 19;82 (1) :412.|Cell Prolif. 2024 Jul 24:e13720.|Cell Rep Med. 2025 Apr 25:102098.|Cell Rep Med. 2025 Jul 15;6 (7) :102215.|Cell Rep. 2024 Feb 17;43 (2) :113804.|Cell Tissue Res. 2024 Jan;395 (1) :63-79.|Cell Transplant. 2023 Jan-Dec:32:9636897231177356.|Cell Transplant. 2025 Jan-Dec:34:9636897251376125.|Cell. 2023 Jun 22;186 (13) :2823-2838.e20.|Ceram Int. 2025 Nov 7.|Chem Eng J. 2023 Aug 6, 145212.|Chem Eng J. 2025 Oct 8;524:169421.|Chem Mater. 2017, 29 (19) :8221-8238.|Chin Herb Med. 2024 Apr 30.|Clin Exp Pharmacol Physiol. 2024 Nov;51 (11) :e13923.|Clin Transl Med. 2023 Jul;13 (7) :e1326.|Collagen Leather. 2025 Nov 19, 7 (1) :39.|Commun Biol. 2022 Nov 26;5 (1) :1295.|Commun Biol. 2024 Nov 28;7 (1) :1589.|Commun Biol. 2025 Aug 27;8 (1) :1291.|Commun Biol. 2025 Jul 29;8 (1) :1127.|Commun Biol. 2025 Jul 30;8 (1) :1134.|Comput Biol Med. 2023 Mar:154:106607.|Curr Biol. 2024 May 21:S0960-9822 (24) 00603-1.|Curr Eye Res. 2022 Aug;47 (8) :1156-1164.|Cytotechnology. 2026 Feb;78 (1) :5.|Dermatol Clin. 2025 August 20.|Drug Des Devel Ther. 2022 Nov 15:16:3929-3946.|Drug Test Anal. 2021 Feb;13 (2) :283-298.|Ecotoxicol Environ Saf. 2021 Aug 16:224:112632.|Ecotoxicol Environ Saf. 2022 Dec 15:248:114315.|Endocr J. 2022 Apr 28;69 (4) :385-397.|Endocrine. 2025 May 24.|Endocrinology. 2022 Dec 19;164 (2) :bqac203.|Eur J Med Chem. 2021 Dec 5:225:113743.|Eur J Med Chem. 2022 Jul 5:237:114382.|Eur J Med Chem. 2023 Oct 5:258:115602.|Eur J Med Chem. 2024 Aug 16:277:116773.|Eur J Pharmacol. 2023 Jan 5:938:175425.|Eur J Pharmacol. 2024 Jun 14:176746.|Eur J Pharmacol. 2025 Dec 5:1008:178303.|Eur J Pharmacol. 2025 Jul 15:999:177433.|Eur J Pharmacol. 2025 Jul 5:998:177534.|Eur J Pharmacol. 2025 Mar 25:177537.|Eur J Pharmacol. 2025 May 15:995:177427.|Eur J Pharmacol. 2026 Jan 10:1010:178362.|Exp Cell Res. 2020 Aug 1;393 (1) :112054.|Exp Cell Res. 2025 Mar 1;446 (1) :114471.|Exp Eye Res. 2018 Mar:168:2-11.|FASEB J. 2021 Feb;35 (2) :e20995.|FASEB J. 2022 Mar;36 (3) :e22147.|Free Radic Biol Med. 2021 Nov 20;176:228-240.|Free Radic Biol Med. 2024 Feb 20:212:309-321.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Free Radic Biol Med. 2025 Aug 13:240:183-196.|Front Med. 2021 Sep 23;8:746298.|Front Pharmacol. 2022 May 5;13:885053.|Front Pharmacol. 2022 Sep 26;13:997701.|Front Pharmacol. 2024 Aug 1:15:1413876.|Front Vet Sci. 2023 Nov 17:10:1277586.|Gene. 2019 Jun 5:700:139-148.|Heliyon. 2022 Aug 13;8 (8) :e10201.|Hematology. 2025 Dec;30 (1) :2545078. |Hum Cell. 2024 Oct 22;38 (1) :4.|Hum Exp Toxicol. 2025 Jan-Dec:44:9603271251324582.|Immunopharmacol Immunotoxicol. 2025 May 29:1-12.|Inflammation. 2024 Jun;47 (3) :853-873.|Int Immunopharmacol. 2020 Nov;88:107003.|Int Immunopharmacol. 2023 Sep:122:110558.|Int Immunopharmacol. 2024 Sep 6;142 (Pt A) :113055.|Int Immunopharmacol. 2025 May 23:159:114894.|Int Immunopharmacol. 2025 May 26:159:114954.|Int Immunopharmacol. 2025 Oct 15:167:115599.|Int J Biol Macromol. 2023 Dec 2;257 (Pt 1) :128588.|Int J Biol Macromol. 2025 Dec;334 (Pt 2) :149132.|Int J Cancer. 2025 Jul 4.|Int J Mol Med. 2023 Sep;52 (3) :78.|Int J Mol Sci. 2023 Jun 29;24 (13) :10838.|Int J Nanomedicine. 2024 Nov 21:19:12369-12387.|Int J Surg. 2025 Jul 2.|Invest Ophthalmol Vis Sci. 2024 Sep 3;65 (11) :21.|iScience. 2021 Sep 25;24 (10) :103170.|iScience. 2025 Apr 22;28 (5) :112513.|iScience. 2025 Apr 3;28 (5) :112344.|iScience. 2025 Jan 17;28 (2) :111831.|J Agric Food Chem. 2025 Jun 4;73 (22) :13891-13901.|J Allergy Clin Immunol. 2025 Sep 17:S0091-6749 (25) 00948-0.|J Biomed Inform. 2023 Jun:142:104383.|J Biomed Sci. 2025 May 30;32 (1) :54.|J Cachexia Sarcopenia Muscle. 2022 Aug;13 (4) :2017-2030.|J Cell Mol Med. 2021 Jan;25 (2) :1089-1099.|J Cell Mol Med. 2023 Dec;27 (23) :3911-3927.|J Cell Mol Med. 2024 Aug;28 (16) :e70044.|J Cereb Blood Flow Metab. 2022 Dec;42 (12) :2230-2244.|J Clin Immunol. 2025 Nov 15;45 (1) :160.|J Control Release. 2025 Nov 19:389:114427.|J Dent Sci. 2022 Jul;17 (3) :1281-1291.|J Ethnopharmacol. 2020 Sep 15;259:112882. |J Ethnopharmacol. 2023 Apr 6:305:116093.|J Ethnopharmacol. 2023 Jan 10:300:115725.|J Ethnopharmacol. 2024 Aug 17:118661.|J Ethnopharmacol. 2024 Aug 27:336:118740.|J Ethnopharmacol. 2024 Mar 1:321:117530.|J Ethnopharmacol. 2024 Nov 29:340:119128.|J Ethnopharmacol. 2024 Sep 13:118831.|J Ethnopharmacol. 2025 Jun 5:120082.|J Ethnopharmacol. 2026 Feb 28:357:120903.|J Extracell Vesicles. 2025 Sep;14 (9) :e70162.|J Funct Foods. 2023, 100: 105386.|J Funct Foods. 2024 Oct.|J Immunol Res. 2019 May 22:2019:8042097.|J Integr Med. 2024 Jan;22 (1) :83-92.|J Integr Neurosci. 2025 Aug 21;24 (8) :39532.|J Invest Surg. 2025 Dec;38 (1) :2535522.|J Mater Chem B. 2022 Oct 5;10 (38) :7847-7861.|J Med Chem. 2019 Jul 25;62 (14) :6561-6574. |J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Med Chem. 2022 Dec 8;65 (23) :15710-15724.|J Med Chem. 2023 Jan 12;66 (1) :473-490.|J Med Chem. 2024 Sep 12;67 (17) :15738-15755.|J Mol Histol. 2024 Aug;55 (4) :503-512.|J Mol Histol. 2025 Aug 6;56 (4) :253.|J Nanobiotechnology. 2021 Dec 2;19 (1) :400.|J Nanobiotechnology. 2025 May 30;23 (1) :398.|J Nat Med. 2023 Mar;77 (2) :251-261.|J Oral Biosci. 2025 Mar;67 (1) :100571.|J Orthop Surg Res. 2025 Nov 14;20 (1) :997.|J Orthop Surg Res. 2025 Oct 29;20 (1) :943.|J Orthop Translat. 2024 Oct 4:49:82-95.|J Pharm Anal. 2025 Aug 9.|J Pharm Biomed Anal. 2016 May 30:124:216-227.|J Pharm Biomed Anal. 2021 Feb 20;195:113825.|J Transl Med. 2024 Dec 3;22 (1) :1095.|Life Sci. 2019 Mar 15:221:168-177.|Mater Today Bio. 2023 May 18:20:100667.|Mater Today Bio. 2025 Jun 21:33:102009.|Mayo Clinic. 2025.|Metabolism. 2025 Mar 30:156252.|Mol Biol Rep. 2024 Apr 21;51 (1) :562.|Mol Biol Rep. 2024 Mar 14;51 (1) :421.|Mol Immunol. 2021 Sep:137:163-173.|Mol Immunol. 2025 Apr:180:44-54.|Mol Med Rep. 2019 Dec; 20 (6) : 4933–4942.|Mol Nutr Food Res. 2024 Apr;68 (7) :e2300343.|Molecules. 2023 May 30;28 (11) :4441.|mSphere. 2024 Nov 21;9 (11) :e0067124.|Nanoscale Adv. 2025 Nov 21.|Nat Chem Biol. 2025 May 22.|Nat Commun. 2025 Aug 26;16 (1) :7954.|Nat Genet. 2024 Apr;56 (4) :663-674.|Nat Prod Bioprospect. 2023 Oct 7;13 (1) :36.|Nat Prod Commun. 2025 Mar 13.|Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397 (11) :8707-8723.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 31.|Neuron. 2025 Oct 10:S0896-6273 (25) 00706-8.|Neuroscience. 2025 Jun 21:577:144-153.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Oncogene. 2021 Sep;40 (35) :5367-5378.|Oxid Med Cell Longev. 2022 Apr 14;2022:4913534.|Oxid Med Cell Longev. 2022 Mar 3;2022:3182368.|Patent. US20180263995A1.|Patent. US20210252159A1.|Patent. US20230404992A1.|Patent. US20240238358A1|Patent. US20240238358A1.|Patent. US20240261359A1.|Patent. US20250025542A1.|Patent. US20250129329A1.|Patent. US20250154468A1.|Pathol Res Pract. 2025 Oct 17;276:156273.|Pharmaceuticals (Basel) . 2025 Feb 25;18 (3) :322.|Pharmaceuticals (Basel) . 2025 Jan 29;18 (2) :181.|Phytomedicine. 2022 Apr:98:153959.|Phytomedicine. 2024 Dec:135:156043.|Phytomedicine. 2024 Dec:135:156168.|Phytomedicine. 2024 May 12:130:155733.|Phytomedicine. 2025 Apr:139:156508.|Phytomedicine. 2025 Feb 10:139:156491.|Phytomedicine. 2025 Feb:137:156362.|Phytomedicine. 2025 Jul:142:156698.|Phytomedicine. 2025 Jun 14:145:156957.|Phytomedicine. 2025 Jun 15:145:156984.|Phytomedicine. 2025 Mar 19:141:156663.|Phytomedicine. 2025 May 29:144:156929.|Phytomedicine. 2025 Oct 11:148:157400.|Phytomedicine. 2025 Oct 16:148:157413.|Phytomedicine. 2025 Oct:146:157091.|Phytomedicine. 2025 Sep 24:148:157306.|Phytomedicine. 2025 Sep 27:148:157336.|Phytother Res. 2024 Nov;38 (11) :5203-5224.|Phytother Res. 2025 Sep 18.|Plant Physiol. 2023 Feb 12;191 (2) :1416-1434.|Preprints. 2025 Sep 24.|Redox Biol. 2025 Aug 13:86:103820.|Redox Rep. 2025 Dec;30 (1) :2565861.|Res Sq. 2025 Jul 21.|Res Sq. 2025 May 08.|Res Sq. 2025 Oct 27.|Research Square Preprint. 2021 Jul.|Research Square Preprint. 2021 Oct.|Research Square Print. 2022 Aug.|Research Square Print. January 4th, 2023.|Sci Rep. 2024 Apr 30;14 (1) :9960.|Sci Rep. 2024 Sep 2;14 (1) :20370.|Sci Rep. 2025 Mar 15;15 (1) :8950.|Sci Rep. 2025 Oct 21;15 (1) :36691.|Sci Rep. 2025 Sep 25;15 (1) :32764.|Small Methods. 2024 Jul 22:e2400660.|Small. 2023 Aug;19 (32) :e2300409.|Small. 2025 Sep 5:e05946.|SSRN. 2022.|SSRN. 2023 Oct 10.|SSRN. 2023 Oct 30.|SSRN. 2023 Sep 11.|SSRN. 2024 Mar 8.|SSRN. 2024 May 30.|SSRN. 2025 Jul 7.|SSRN. 2025 Jun 3.|SSRN. 2025 Mar 31.|SSRN. 2025 Sep 11.|Stem Cell Res Ther. 2023 Dec 20;14 (1) :333.|Stem Cell Res Ther. 2024 Nov 28;15 (1) :456.|Stem Cell Res. 2021 Mar:51:102175.|Theranostics. 2025 Aug 16;15 (17) :9131-9158.|Toxicol Appl Pharmacol. 2024 Nov:492:117127.|Toxicol Appl Pharmacol. 2025 Aug 11:504:117510.|Toxicol Lett. 2019 Jul:309:42-50.|Transl Psychiatry. 2021 Mar 26;11 (1) :185.|Universidad de Navarra. 2024 Feb 28.|Utah State University. 2023 Feb 1.|World J Tradit Chin Med. 2025 Oct 28.|Antioxidants (Basel) . 2025 Apr 1;14 (4) :428.|Biochem Pharmacol. 2025 Sep 17;242 (Pt 3) :117342.

• CAS Number:

  [50-02-2]